Objective. To ascertain whether AS-associated polymorphisms of ERAP1, IL23R and IL12B genes associate with subphenotypes of PsA, particularly axial radiographic disease once stratified by HLA-B27 and HLA-Cw*0602 status.
Introduction
PsA is an inflammatory arthritis affecting between 7% and 42% of psoriasis patients. The overlapping clinical phenotype of PsA and AS suggests common pathogenic mechanisms. The diseases are likely to share pro-inflammatory cytokine pathways that culminate in altered innate and adaptive immune systems. HLA-B27 [1] , HLA-Cw*0602 [2] , IL12B [3] , IL-23 receptor (IL23R) [3, 4] , late cornified envelope gene cluster [5] and TRAF3IP2 [6] genes, among others, have shown association with PsA. Of these, the IL23R, IL12B and HLA-B27 polymorphisms have also shown association with AS [79] .
A promising new candidate gene, endoplasmic reticulum aminopeptidase 1 (ERAP1), codes for a trimming aminopeptidase located in the endoplasmic reticulum that has a function in MHC class 1 peptide presentation. ERAP1 gene locus polymorphisms have shown robust association with AS [9, 10] and psoriasis [11] .
We hypothesize that ERAP1 single nucleotide polymorphisms (SNPs) may identify a subgroup of PsA patients with a clinical phenotype more like AS. Studies in psoriasis suggest that ERAP1 is only significantly associated with disease if a patient carries at least one copy of the minor allele of HLA-Cw*0602, and is more strongly associated if subjects are homozygous for the HLA-Cw*0602 allele [11] . Similarly the association of ERAP1 with AS has been shown to be dependent on HLA-B27 status [9] . This study aims to investigate AS-associated genes ERAP1, IL23R and IL12B for association with both PsA and specific PsA clinical subphenotypes, stratified by HLACw*0602 and HLA-B27 status.
Methods
An observational study conducted at the Royal National Hospital for Rheumatic Diseases in Bath since 1988 provided prospective data from patients attending a dedicated PsA outpatient clinic. PsA cases living in SouthWest England of homogeneous white Caucasian ancestry without significant influences by migration or founder population effects were compared with data from healthy controls derived from the Wellcome Trust Case Control Consortium (WTCCC).
The following clinical subphenotypes were investigated; sex, age at onset of psoriasis (type 1 psoriasis defined as onset <40 years of age, type 2 psoriasis defined as onset 540 years of age), age at onset of PsA, joint pattern at PsA onset (polyarticular being five or more joints involved), presence/absence of peripheral radiographic erosions, Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), Psoriasis Area and Severity Index (PASI) score, nail score and presence or absence of axial radiographic disease.
Some patients had axial radiographs dating back to 1974 and at multiple time points. Therefore the most recent radiographs to allow a complete set were used. Radiographs were read by D.J., W.T. and D.W. following education by a consultant radiologist and quality assurance checks for inter-rater reliability. Radiographic axial disease was defined as the presence of New York criteria unilateral/bilateral sacroiliitis of grade 52 on pelvic radiograph and/or 51 marginal/paramarginal syndesmophyte(s) of the cervical, thoracic or lumbar spine [12] .
Four candidate SNPs were selected for genotyping based on previous studies [3, 4, 11] . A total of 263 PsA cases were genotyped at the Arthritis Research UK Epidemiology Unit in Manchester, UK, using standard protocols for iPLEX Sequenom MassARRAY assays (Sequenom Inc., USA). Genotype data from cases were compared with data from WTCCC controls; 3266 controls for ERAP1 (rs30187), 5422 for IL12B (rs6887695) and 4941 for IL23R (rs11209026 and rs7530511) genes. Genotype data for HLA-Cw*0602 (rs10484554; n = 199) and HLA-B27 (rs4349859; n = 207) were obtained by imputation for the PsA cases.
Data were analysed using SPSS-17 (IBM Corp., Armonk, NY, USA). Allele and genotype frequencies were tested for HardyWeinberg equilibrium. Allele and genotype carriage frequency in PsA cases and controls was compared using the Pearson chi-squared test with Yates Continuity Correction test for parametric data and MannWhitney U-test for non-parametric data. Odds ratios (ORs), 95% CIs and inter-quartile ranges (IQRs) were calculated. The power to detect an effect size of 1.5 at the 5% significance level varied between 49% (111 cases vs 3266 controls, MAF 40% for HLA-Cw*0602 analysis) and 89% (263 cases vs 5422 controls, MAF 30% for ERAP1) [13] . Ethical approval for the study was given by the Bath Regional Ethics Committee and informed written consent obtained from participants.
Results
A total of 263 PsA cases were studied (132 males). Of the total cases, 98.5% fulfilled the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA [14] . Median age at psoriasis onset was 28 years (IQR 1743 years). Median age at PsA onset was 38 years (IQR 2950 years). Most patients had type 1 psoriasis (n = 173; 74%). During the period of data collection, 69 (26%) cases demonstrated evidence of radiographic axial disease, 47 (18%) radiographic sacroiliitis and 87 (33%) peripheral radiographic erosions. The median HAQ score was 0.63 (IQR 0.311.39), median PASI score 2.15 (IQR 0.614.04) and median nail score 2.26 (IQR 0.256.67).
Genotype frequencies in cases and controls were in HardyWeinberg equilibrium. Control genotype frequencies were comparable to those in the published literature [3, 4] . rs30187 (ERAP1) genotype frequencies were similar in cases and controls (OR 0.99; 95% CI 0.65, 1.50; P = 0.999). No association was identified with any clinical parameter, including the presence/absence of radiographic axial disease (OR 0.79; P = 0.49) ( Table 1) .
A strong association was demonstrated between rs6887595 (IL12B) and PsA, with homozygosity of the major allele (G) being more frequent in PsA cases (57.9%) than controls (44.7%) (OR 1.70, 95% CI 1.32, 2.18; P < 0.001). No association was found with clinical parameters (Table 1) . rs11209026 (IL23R) genotype frequencies were similar in cases and controls (OR 1.13; 95% CI 0.76, 1.66; P = 0.618). Table 1 demonstrates a trend for the minor allele (A) of rs11209026 to be less frequent in patients with erosive joint disease (7%) than in those without erosion (14%) or controls (12%) (OR 0.47; P = 0.16). rs7530511 (IL23R) genotype frequencies were similar in cases and controls (OR 1.21; 95% CI 0.89, 1.65; P = 0.250). No association was found with clinical parameters (Table 1) . HLA-Cw*0602 was more frequent in patients with type 1 psoriasis (46%) than in those with type 2 psoriasis (25%) (OR 2.64; P = 0.014) ( Table 1) . Table 2 shows the results of tests of association between ERAP1 and either radiographic axial disease or sacroiliitis, stratified according to HLA-Cw*0602 status. PsA cases carrying the minor allele of rs30187 were equally likely to experience radiographic axial disease or sacroiliitis, irrespective of HLA-Cw*0602 status. (14) www.rheumatology.oxfordjournals.org Table 2 shows the results of tests of association between ERAP1 and either radiographic axial disease or sacroiliitis, stratified according to HLA-B27 status. PsA cases carrying the minor allele of rs30187 were equally likely to experience radiographic axial disease or sacroiliitis, irrespective of HLA-B27 status.
Discussion
PsA may be regarded as part of the broad continuum of spondyloarthritis (SpA) that comprises AS, ReA, enteropathic arthritis, juvenile SpA and undifferentiated SpA. Genetic studies in psoriatic disease to date have largely focused on identifying susceptibility genes rather than addressing association with subphenotypes of PsA. We have taken advantage of a well-characterized cohort of PsA patients followed prospectively in a single centre to investigate whether AS-associated genes may be associated with axial disease in PsA.
A similar study investigating rs11209026 (IL23R) using a different definition of axial disease (inflammatory back pain with either reduced spinal range of movement or radiographic axial changes) found no difference in allele frequency among PsA patients with/without axial disease [4] . In clinical practice, patients may be defined as psoriatic SpA based on clinical criteria, radiographic criteria or both. Clinical criteria are prone to inter-assessor disagreement, patient recall and without agreed definition. We chose radiographic criteria to define axial disease as it is less subjective, more reproducible and no previously published genetic association studies have characterized such a large cohort of PsA cases in such a manner.
We have confirmed a statistically significant association between rs6887595 (IL12B) and PsA. We have found a trend between rs11209026 (IL23R) and peripheral erosive joint disease. If confirmed in larger studies, this may suggest that rs11209026 is a prognostic marker. IL12B and IL23R genes mediate a cascade of events that stimulate naïve CD4 + T cells to differentiate into novel Th17 cells producing IL-17; a pro-inflammatory cytokine that enhances T-cell priming and stimulates the production of pro-inflammatory IL-1, IL-6, TNF-a and nitric oxide synthase. According to Murphy et al. [15] , IL23R gene knockout mice are less prone to arthritis, perhaps due to an absence of IL-17 producing CD4 + T cells.
However, IL12B gene knockout mice are more prone to arthritis, possibly because they paradoxically develop more IL-17 producing CD4 + T cells. A novel monoclonal antibody is now licensed for the treatment of psoriasis in adults that neutralizes IL-12 and IL-23 cytokines by binding the common p40 subunit. Psoriasis and PsA patients treated with this antibody experience improved skin and joint scores [16] , implying that despite the genetic evidence that IL12B and IL23R genes are primarily associated with psoriasis, the pathway remains important in PsA. We have replicated our own previously reported findings [17] and that of another study [2] showing an association between HLA-Cw*0602 and PsA cases experiencing earlier-onset type 1 psoriasis. A genome-wide association study identified ERAP1 as a candidate gene for AS, with an estimated population-attributable risk of 26%, far higher than another associated gene, IL23R (9%) [10] . Independent studies have replicated the association between rs30187 and AS on genotype and haplotype analysis [18] . rs30187 is a non-synonymous SNP, resulting in a missense mutation of lysine to arginine at codon 528. Preliminary studies suggest that the rs30187 polymorphism results in reduced substrate-binding affinity in the ERAP1 enzyme cleft [19] . The ERAP1 gene encodes a multi-functional zinc metallopeptidase. Peptide fragments 916 residues in length derived from intracellular proteins are trimmed and presented on the cell surface via the MHC class 1 molecule to CD8 + T cells. ERAP1
thus catalyses a rate-limiting step in MHC 1 molecule antigen presentation. The ERAP1ERAP2 haplotype is thought to influence the HLA-B27 restricted peptide repertoire, folding mechanisms and heavy chain dimer formation [18] . Our study is unique in exploring ERAP1 polymorphisms in PsA, but we have not demonstrated an association between rs30187 (ERAP1) and PsA or PsA subphenotypes. Furthermore, on stratifying our data according to HLACw*0602 and HLA-B27 status we did not find any association with radiographic axial disease or sacroiliitis. We acknowledge that our sample size is relatively small and may not be sufficiently powered to detect anything other than strong associations between ERAP1 and axial disease in PsA, and needs further testing in a larger dataset. Nonetheless, our findings suggest that spinal involvement in psoriatic disease is not genetically identical to that in AS, which is in keeping with observations that the clinical and radiographic pattern of axial disease also differs in the two conditions.
Rheumatology key messages
. Spinal involvement in psoriatic disease may be genetically different from that in AS. . ERAP1 appears not to be associated with axial radiographic disease in PsA. . The IL23R variant (rs11209026) needs further investigation as a prognostic marker for peripheral erosive disease.
